EA200000141A1 - Способ лечения диабета тиазолидиндионом и сульфонилмочевиной - Google Patents

Способ лечения диабета тиазолидиндионом и сульфонилмочевиной

Info

Publication number
EA200000141A1
EA200000141A1 EA200000141A EA200000141A EA200000141A1 EA 200000141 A1 EA200000141 A1 EA 200000141A1 EA 200000141 A EA200000141 A EA 200000141A EA 200000141 A EA200000141 A EA 200000141A EA 200000141 A1 EA200000141 A1 EA 200000141A1
Authority
EA
Eurasian Patent Office
Prior art keywords
diabetas
thiazolidindione
uride
sulfonyl
treatment
Prior art date
Application number
EA200000141A
Other languages
English (en)
Other versions
EA003303B1 (ru
Inventor
Робин Эдвин Бакингэм
Стефен Элистэр Смит
Original Assignee
Смитклайн Бичам Плс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10816177&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200000141(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Смитклайн Бичам Плс filed Critical Смитклайн Бичам Плс
Publication of EA200000141A1 publication Critical patent/EA200000141A1/ru
Publication of EA003303B1 publication Critical patent/EA003303B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Описаны способ лечения сахарного диабета и состояний, связанных с сахарным диабетом, у млекопитающего, предусматривающий введение эффективного нетоксичного и фармацевтически приемлемого количества сенсибилизатора инсулина и субмаксимального количества средства, усиливающего секрецию инсулина млекопитающему, нуждающемуся в этом, и фармацевтическая композиция для применения в этом способе.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200000141A 1997-07-18 1998-07-16 Способ лечения диабета тиазолидиндионом и сульфонилмочевиной EA003303B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9715306A GB9715306D0 (en) 1997-07-18 1997-07-18 Novel method of treatment
PCT/GB1998/002109 WO1999003476A1 (en) 1997-07-18 1998-07-16 Treatment of diabetes with thiazolidinedione and sulphonylurea

Publications (2)

Publication Number Publication Date
EA200000141A1 true EA200000141A1 (ru) 2000-08-28
EA003303B1 EA003303B1 (ru) 2003-04-24

Family

ID=10816177

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200000141A EA003303B1 (ru) 1997-07-18 1998-07-16 Способ лечения диабета тиазолидиндионом и сульфонилмочевиной

Country Status (41)

Country Link
EP (1) EP0998291B2 (ru)
JP (2) JP2001510158A (ru)
KR (1) KR100680667B1 (ru)
CN (1) CN1264302A (ru)
AP (1) AP1318A (ru)
AR (2) AR016768A1 (ru)
AT (1) ATE366577T1 (ru)
AU (1) AU743269B2 (ru)
BG (1) BG64892B1 (ru)
BR (1) BR9810904A (ru)
CA (1) CA2297115C (ru)
CO (1) CO4940422A1 (ru)
CY (1) CY1107745T1 (ru)
CZ (1) CZ302668B6 (ru)
DE (1) DE69838066T3 (ru)
DK (1) DK0998291T4 (ru)
DZ (1) DZ2564A1 (ru)
EA (1) EA003303B1 (ru)
ES (1) ES2290989T5 (ru)
GB (1) GB9715306D0 (ru)
HK (1) HK1029272A1 (ru)
HU (1) HU229119B1 (ru)
ID (1) ID24198A (ru)
IL (1) IL134045A0 (ru)
IN (1) IN189035B (ru)
MA (1) MA26522A1 (ru)
MY (1) MY138246A (ru)
NO (1) NO326356B1 (ru)
NZ (3) NZ520652A (ru)
OA (1) OA11632A (ru)
PE (1) PE99799A1 (ru)
PL (2) PL338127A1 (ru)
PT (1) PT998291E (ru)
SI (1) SI0998291T2 (ru)
SK (2) SK288053B6 (ru)
TR (1) TR200000135T2 (ru)
TW (1) TW586926B (ru)
UA (1) UA70302C2 (ru)
UY (1) UY25103A1 (ru)
WO (1) WO1999003476A1 (ru)
ZA (1) ZA986365B (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1897547A1 (en) * 1999-07-13 2008-03-12 Medicure Inc. Use of pyridoxal phosphate derivatives for the treatment of diabetes and related complications
EP1832291A3 (en) * 1999-07-13 2009-11-04 Medicure Inc. use of pyridoxal phosphate for the treatment of diabetes and related complications
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
US20010036479A1 (en) 2000-01-14 2001-11-01 Gillian Cave Glyburide composition
EP1738751B1 (en) 2001-01-12 2011-05-11 Sun Pharma Advanced Research Company Ltd Spaced drug delivery system
CA2540225C (en) 2003-10-31 2012-03-06 Takeda Pharmaceutical Company Limited Solid preparation of pioglitazone, glimepiride and a polyoxyethylene sorbitan fatty acid ester
JP2008019169A (ja) * 2004-10-25 2008-01-31 Osaka Univ 新規ｐｐａｒ調節剤およびそのスクリーニング方法
ZA200805147B (en) 2005-12-22 2010-05-26 Takeda Pharmaceutical Solid preparation

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) * 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
US4582839A (en) * 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
JPH06779B2 (ja) * 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US4812570A (en) * 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
ATE186724T1 (de) * 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
US4791125A (en) * 1987-12-02 1988-12-13 Pfizer Inc. Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
US5061717A (en) * 1988-03-08 1991-10-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
WO1989008651A1 (en) * 1988-03-08 1989-09-21 Pfizer Inc. Hypoglycemic thiazolidinedione derivatives
WO1991007107A1 (en) * 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
JPH04210683A (ja) * 1990-12-06 1992-07-31 Terumo Corp チアゾリジン−２，４−ジオン誘導体およびこれを含有する糖尿病合併症治療薬
US5183823A (en) * 1991-04-11 1993-02-02 Takeda Chemical Industries, Ltd. Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents
EP0528764B1 (en) * 1991-08-16 1996-06-12 Sandoz Ltd. Inhaler for administration of powdery substances
ES2101866T3 (es) * 1991-08-26 1997-07-16 Upjohn Co Producto alimentario liquido que contiene acido 3-guanidinopropionico.
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes

Also Published As

Publication number Publication date
SI0998291T2 (sl) 2011-10-28
KR100680667B1 (ko) 2007-02-09
NO20000229L (no) 2000-01-17
UY25103A1 (es) 2000-12-29
KR20010021948A (ko) 2001-03-15
WO1999003476A1 (en) 1999-01-28
NO20000229D0 (no) 2000-01-17
TR200000135T2 (tr) 2000-05-22
PT998291E (pt) 2007-10-11
NO326356B1 (no) 2008-11-17
PL199125B1 (pl) 2008-08-29
ZA986365B (en) 2000-01-17
HUP0003634A3 (en) 2003-04-28
AP2000001734A0 (en) 2000-03-31
CA2297115A1 (en) 1999-01-28
NZ515555A (en) 2002-09-27
MA26522A1 (fr) 2004-12-20
OA11632A (en) 2004-11-22
ATE366577T1 (de) 2007-08-15
NZ520652A (en) 2004-06-25
AR016768A1 (es) 2001-08-01
SK602000A3 (en) 2000-07-11
DE69838066T3 (de) 2012-03-29
CZ2000173A3 (en) 2001-05-16
HUP0003634A2 (hu) 2001-07-30
ES2290989T5 (es) 2011-11-11
IL134045A0 (en) 2001-04-30
PE99799A1 (es) 1999-12-22
DK0998291T4 (da) 2011-09-26
AU743269B2 (en) 2002-01-24
AP1318A (en) 2004-10-22
UA70302C2 (ru) 2004-10-15
DZ2564A1 (fr) 2003-02-15
DE69838066D1 (de) 2007-08-23
BR9810904A (pt) 2000-09-26
MY138246A (en) 2009-05-29
CA2297115C (en) 2010-02-23
NZ501256A (en) 2002-09-27
ES2290989T3 (es) 2008-02-16
TW586926B (en) 2004-05-11
EP0998291B1 (en) 2007-07-11
EP0998291A1 (en) 2000-05-10
AU8448798A (en) 1999-02-10
BG104139A (en) 2000-11-30
SK288053B6 (sk) 2013-03-01
HU229119B1 (en) 2013-08-28
PL338127A1 (en) 2000-09-25
JP2001510158A (ja) 2001-07-31
ID24198A (id) 2000-07-13
EP0998291B2 (en) 2011-07-06
DK0998291T3 (da) 2007-11-05
SK287823B6 (sk) 2011-11-04
HK1029272A1 (en) 2001-03-30
IN189035B (ru) 2002-12-07
DE69838066T2 (de) 2008-03-20
EA003303B1 (ru) 2003-04-24
CO4940422A1 (es) 2000-07-24
CN1264302A (zh) 2000-08-23
CY1107745T1 (el) 2013-04-18
JP2005247865A (ja) 2005-09-15
SI0998291T1 (sl) 2007-12-31
GB9715306D0 (en) 1997-09-24
AR019331A2 (es) 2002-02-13
BG64892B1 (bg) 2006-08-31
CZ302668B6 (cs) 2011-08-24

Similar Documents

Publication Publication Date Title
EA200000041A1 (ru) Способ лечения диабета тиазолидиндионом и метформином
EA200100541A1 (ru) Фармацевтическая композиция с модифицированным высвобождением сенсибилизатора к инсулину и других антидиабетических агентов
EA200300036A1 (ru) Комбинации ингибиторов дипептидилпептидазы iv и других антидиабетических агентов для лечения сахарного диабета
EA200100029A1 (ru) ГЛЮКАГОНОПОДОБНЫЙ ПЕПТИД-1, УЛУЧШАЮЩИЙ ОТВЕТ β-КЛЕТОК НА ГЛЮКОЗУ У СУБЪЕКТОВ С НАРУШЕНИЕМ ТОЛЕРАНТНОСТИ К ГЛЮКОЗЕ
EA200000468A1 (ru) Терапевтическая композиция для введения толтеродина с контролируемым высвобождением
EA200100289A1 (ru) Способ введения инсулинотропных пептидов
RU95108231A (ru) Glp-1-молекулярный комплекс, фармацевтическая композиция и способ получения комплекса
EA200101089A1 (ru) Новый способ лечения
EA200000139A1 (ru) Лечение диабета тиазолидиндионом, средством, стимулирующим секрецию инсулина, и дигуанидом
EA200000042A1 (ru) Способ лечения диабета росиглитазоном и инсулином
EA200000141A1 (ru) Способ лечения диабета тиазолидиндионом и сульфонилмочевиной
BR9810292A (pt) Tratamento de diabete com tiazolidinadiona, secretagogo de insulina e inibidor de alfa-glicosidase
BR9810142A (pt) Tratamento de diabete com tiazolidinadiona e sulfonil-uréia
BR9915214A (pt) Combinações contendo um beta-agonista e umagente anti-diabético adicional
AR013352A1 (es) Uso de un sensibilizador a insulina y un agente antihiperglucemico para la preparacion de un medicamento para el tratamiento de la diabetes mellitus ycondiciones asociadas a la misma y una composicion farmaceutica.
EA199800177A1 (ru) Способ снижения количества экзогенного инсулина, вводимого пациенту с инсулиннезависимым сахарным диабетом
SE8804640D0 (sv) Medicament comprising cyclolinopeptide a
ECSP982593A (es) Nuevo metodo de tratamiento vi
KR920702676A (ko) 신규 입체이성질체
EA200700968A1 (ru) Фармацевтическая композиция для лечения сахарного диабета 2 типа
WO2001047509A3 (en) Composition for the treatment diabetes mellitus containing an insuline sensitizer and agent used in the treatment of cardiac conditions
BR9813037A (pt) Composto, processo para sua preparação, uso do mesmo, preparação farmacêutica, e, combinação desta com pelo menos uma outra substância ativa
RU96122371A (ru) Способ лечения эндогенных и послеоперационных увеитов
EA200000418A1 (ru) Применение тиазолидиндионов для лечения гипергликемии
ECSP982591A (es) Nuevo metodo de tratamiento iv

Legal Events

Date Code Title Description
ND4A Extension of term of a eurasian patent

Designated state(s): AM AZ BY KZ KG MD TJ TM

MK4A Patent expired

Designated state(s): AM AZ BY KZ KG MD TJ TM